Boehringer Forges $7bn Alliance with China's SBP Group

Boehringer forges $7bn alliance with China's SBP Group

Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T cell engagers from China's Sino Biopharma.

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies

Partnership provides opportunities to further expand Boehringer Ingelheim’s portfolio of antibody-drug conjugates (ADCs) and T-cell engagers (TcEs)Agreement reinforces Boehringer Ingelheim’s long-term commitment to China’s innovation ecosystem and validates SBP Group’s innovative R&D capabilitiesSBP Group to receive US$358 million in upfront…

Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical

The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. The post Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical appeared first on GEN - Genetic Engineering and Biotechnology News.

Boehringer secures six Chinese cancer programs in deal worth up to $7B - European Biotechnology Magazine

Boehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical programs involving antibody-drug conjugates (ADCs) and T-cell engagers are expected to strengthen its oncology pipeline. Boehringer will initially pay $358 million, with up to another $7 billion tied to development and commercial milestones.